ABEO
Price
$6.28
Change
+$0.02 (+0.32%)
Updated
Aug 11 closing price
Capitalization
321.78M
6 days until earnings call
CMMB
Price
$0.94
Change
-$0.03 (-3.09%)
Updated
Aug 11, 04:59 PM (EDT)
Capitalization
20.14M
Earnings call today
Interact to see
Advertisement

ABEO vs CMMB

Header iconABEO vs CMMB Comparison
Open Charts ABEO vs CMMBBanner chart's image
Abeona Therapeutics
Price$6.28
Change+$0.02 (+0.32%)
Volume$595.66K
Capitalization321.78M
Chemomab Therapeutics
Price$0.94
Change-$0.03 (-3.09%)
Volume$1.68K
Capitalization20.14M
ABEO vs CMMB Comparison Chart in %
Loading...
ABEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CMMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABEO vs. CMMB commentary
Aug 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABEO is a StrongBuy and CMMB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 12, 2025
Stock price -- (ABEO: $6.26 vs. CMMB: $0.97)
Brand notoriety: ABEO and CMMB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABEO: 47% vs. CMMB: 117%
Market capitalization -- ABEO: $321.78M vs. CMMB: $19.62M
ABEO [@Biotechnology] is valued at $321.78M. CMMB’s [@Biotechnology] market capitalization is $19.62M. The market cap for tickers in the [@Biotechnology] industry ranges from $96.01B to $0. The average market capitalization across the [@Biotechnology] industry is $1.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABEO’s FA Score shows that 0 FA rating(s) are green whileCMMB’s FA Score has 1 green FA rating(s).

  • ABEO’s FA Score: 0 green, 5 red.
  • CMMB’s FA Score: 1 green, 4 red.
According to our system of comparison, ABEO is a better buy in the long-term than CMMB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABEO’s TA Score shows that 5 TA indicator(s) are bullish while CMMB’s TA Score has 2 bullish TA indicator(s).

  • ABEO’s TA Score: 5 bullish, 5 bearish.
  • CMMB’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, ABEO is a better buy in the short-term than CMMB.

Price Growth

ABEO (@Biotechnology) experienced а -3.54% price change this week, while CMMB (@Biotechnology) price change was -5.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +22.22%. For the same industry, the average monthly price growth was +31.78%, and the average quarterly price growth was +19.63%.

Reported Earning Dates

ABEO is expected to report earnings on Aug 18, 2025.

CMMB is expected to report earnings on Nov 07, 2025.

Industries' Descriptions

@Biotechnology (+22.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABEO($322M) has a higher market cap than CMMB($20.1M). ABEO YTD gains are higher at: 12.747 vs. CMMB (-46.414). CMMB has higher annual earnings (EBITDA): -14.18M vs. ABEO (-36.93M). ABEO has more cash in the bank: 84.2M vs. CMMB (10.6M). CMMB has less debt than ABEO: CMMB (292K) vs ABEO (24M). ABEO (0) and CMMB (0) have equivalent revenues.
ABEOCMMBABEO / CMMB
Capitalization322M20.1M1,602%
EBITDA-36.93M-14.18M260%
Gain YTD12.747-46.414-27%
P/E RatioN/AN/A-
Revenue00-
Total Cash84.2M10.6M794%
Total Debt24M292K8,219%
FUNDAMENTALS RATINGS
ABEO vs CMMB: Fundamental Ratings
ABEO
CMMB
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
26
Undervalued
PROFIT vs RISK RATING
1..100
10099
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
4489
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CMMB's Valuation (26) in the Biotechnology industry is somewhat better than the same rating for ABEO (59) in the Pharmaceuticals Generic industry. This means that CMMB’s stock grew somewhat faster than ABEO’s over the last 12 months.

CMMB's Profit vs Risk Rating (99) in the Biotechnology industry is in the same range as ABEO (100) in the Pharmaceuticals Generic industry. This means that CMMB’s stock grew similarly to ABEO’s over the last 12 months.

CMMB's SMR Rating (99) in the Biotechnology industry is in the same range as ABEO (100) in the Pharmaceuticals Generic industry. This means that CMMB’s stock grew similarly to ABEO’s over the last 12 months.

ABEO's Price Growth Rating (44) in the Pharmaceuticals Generic industry is somewhat better than the same rating for CMMB (89) in the Biotechnology industry. This means that ABEO’s stock grew somewhat faster than CMMB’s over the last 12 months.

ABEO's P/E Growth Rating (100) in the Pharmaceuticals Generic industry is in the same range as CMMB (100) in the Biotechnology industry. This means that ABEO’s stock grew similarly to CMMB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABEOCMMB
RSI
ODDS (%)
Bearish Trend 4 days ago
83%
Bullish Trend 4 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
86%
N/A
Momentum
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 4 days ago
89%
MACD
ODDS (%)
Bearish Trend 4 days ago
77%
Bearish Trend 4 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 4 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
83%
Bearish Trend 4 days ago
90%
Advances
ODDS (%)
Bullish Trend 13 days ago
84%
N/A
Declines
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
85%
Bullish Trend 4 days ago
85%
Aroon
ODDS (%)
Bullish Trend 4 days ago
83%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ABEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CMMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NXDR2.070.24
+13.11%
Nextdoor Holdings Inc
CRNT1.990.15
+8.15%
Ceragon Networks Ltd
CCEP94.761.54
+1.65%
Coca-Cola Europacific Partners plc
MSW1.51N/A
N/A
Ming Shing Group Holdings Ltd
FTDR54.88-1.44
-2.56%
Frontdoor

ABEO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABEO has been loosely correlated with ZYME. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ABEO jumps, then ZYME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABEO
1D Price
Change %
ABEO100%
+0.32%
ZYME - ABEO
48%
Loosely correlated
+3.49%
ERAS - ABEO
45%
Loosely correlated
+5.71%
CRNX - ABEO
45%
Loosely correlated
+1.97%
ELVN - ABEO
42%
Loosely correlated
+2.40%
IPSC - ABEO
42%
Loosely correlated
-3.49%
More

CMMB and

Correlation & Price change

A.I.dvisor indicates that over the last year, CMMB has been loosely correlated with OVID. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if CMMB jumps, then OVID could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CMMB
1D Price
Change %
CMMB100%
-0.01%
OVID - CMMB
33%
Loosely correlated
+0.66%
OCGN - CMMB
29%
Poorly correlated
-0.16%
ABEO - CMMB
29%
Poorly correlated
-0.16%
COGT - CMMB
29%
Poorly correlated
+0.92%
HURA - CMMB
29%
Poorly correlated
-5.35%
More